Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Maeda

Showing results (271-280 of 276) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 276 results.
Med (New York, N.Y.)|March 9, 2022
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variantsSho Miyamoto, Takeshi Arashiro, Yu Adachi, et al.
Global Health & Medicine|March 3, 2023
Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in JapanReiko Shimbashi, Teiichiro Shiino, Akira Ainai, et al.
NEJM Evidence|February 27, 2024
Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy AdultsEriko Morino, Sohtaro Mine, Noriko Tomita, et al.
The Journal of Infectious Diseases|November 16, 2013
The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in JapanToru Takahashi, Ken Maeda, Tadaki Suzuki, et al.
Nature|May 16, 2022
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2Ryuta Uraki, Maki Kiso, Shun Iida, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 18, 2021
Characterization of a new SARS-CoV-2 variant that emerged in BrazilMasaki Imai, Peter J Halfmann, Seiya Yamayoshi, et al.
Pageof 28

Showing results (271-280 of 276) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 276 results.
Med (New York, N.Y.)|March 9, 2022
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variantsSho Miyamoto, Takeshi Arashiro, Yu Adachi, et al.
Global Health & Medicine|March 3, 2023
Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in JapanReiko Shimbashi, Teiichiro Shiino, Akira Ainai, et al.
NEJM Evidence|February 27, 2024
Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy AdultsEriko Morino, Sohtaro Mine, Noriko Tomita, et al.
The Journal of Infectious Diseases|November 16, 2013
The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in JapanToru Takahashi, Ken Maeda, Tadaki Suzuki, et al.
Nature|May 16, 2022
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2Ryuta Uraki, Maki Kiso, Shun Iida, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 18, 2021
Characterization of a new SARS-CoV-2 variant that emerged in BrazilMasaki Imai, Peter J Halfmann, Seiya Yamayoshi, et al.
Pageof 28